Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Aug 21, 2024 9:01pm
203 Views
Post# 36191047

RE:Research Capital?

RE:Research Capital?
livermore2 wrote: Anyone know why they don't seem to cover theralase any longer. Haven't seen any recent write ups from Andre Uddin. Appreciate if anyone has any info on this as I believe RC was involved with the warrants expiring tomorrow.



It has been ~1 yr since Uddin's last client update.  In August 2023 he reported he was very bullish on Theralase & gave a "speculative buy" rating & a 1 year price target of $0.80, which equated to a 255% return at the time of publication (sp hovering in the $0.17-0.20 range at the time).  Well, we are far from that target, which may explain his silence.  To his defense, I believe many of us thought it would have been higher by now.  

It's no surprise for me that our listing on this venture exchange, the challenges of having such limited operational/reserve funds thus far & the lack of investor/public awareness continue to act as anchors on our sp.  That should change shortly = more than an echo this time around...imo.

<< Previous
Bullboard Posts
Next >>